Current and future management of chronic spontaneous urticaria and chronic inducible urticaria

Toan T. Do, Ethan A. Canty, Shyam R. Joshi

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Background: Chronic urticaria (CU), characterized by ≥6 weeks of intense pruritus, remains a debilitating condition for patients. New and safe treatments are needed to manage CU recalcitrant to standard therapy. Objective: A review of the current literature of standard and novel therapeutics in the management of CU was conducted. Methods: A literature search via a medical literature data base and clinical trial data base was conducted to identify treatment options for CU and current clinical trials. Results: Second-generation antihistamines, omalizumab, and cyclosporine remain the most proven therapeutic options for CU. Dupilumab, mepolizumab, benralizumab, tezepelumab, and CDX-0159 are all undergoing clinical trials for CU. Although ligelizumab demonstrated initial promising results, a phase III study was discontinued due to a nonsuperior clinical impact compared with omalizumab. Conclusion: Novel therapies are needed for the treatment of recalcitrant CU. With a deeper understanding of the pathophysiology of CU, promising therapeutics are in clinical trials for CU.

Original languageEnglish (US)
Pages (from-to)3-14
Number of pages12
JournalAllergy and Asthma Proceedings
Issue number1
StatePublished - Jan 1 2023

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Current and future management of chronic spontaneous urticaria and chronic inducible urticaria'. Together they form a unique fingerprint.

Cite this